Short Interest in PicoCELA Inc. (NASDAQ:PCLA) Decreases By 89.5%

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 12,084 shares, a decrease of 89.5% from the November 30th total of 114,853 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 130,843 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 130,843 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PicoCELA in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

PicoCELA Trading Down 35.5%

Shares of NASDAQ:PCLA traded down $0.13 during trading on Wednesday, reaching $0.23. 19,166,725 shares of the stock were exchanged, compared to its average volume of 41,410,808. The firm’s 50-day moving average price is $0.32 and its 200 day moving average price is $0.65. PicoCELA has a 12-month low of $0.12 and a 12-month high of $9.80. The company has a quick ratio of 1.74, a current ratio of 2.19 and a debt-to-equity ratio of 0.03.

Hedge Funds Weigh In On PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd purchased a new stake in shares of PicoCELA Inc. (NASDAQ:PCLA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA as of its most recent filing with the Securities and Exchange Commission (SEC).

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.